胶质瘤患者治疗相关中期认知后遗症
研究纳入86例WHO 1-4级胶质瘤患者,2004至2012年在德国胶质瘤网络前瞻性随访,采用NeuroCog FX评估注意力、记忆和执行功能。术后中位16.8个月随访显示,放疗、化疗或放化疗联合与无辅助治疗组认知变化无差异,仅照射患者图形记忆改善较少(p=0.029,η2=0.06)。
要点
- 标准放疗、化疗或联合治疗在术后两年内未对WHO 1-4级胶质瘤患者认知功能产生有害影响。
- 仅图形记忆方面,照射患者改善少于未照射患者(p=0.029,η2=0.06)。
- 切除患者所有认知域均改善,活检患者未改善;少突胶质细胞瘤患者注意和执行功能改善潜力大于星形细胞瘤患者。
核心结论
- 术后两年内,放疗、化疗或其联合作为标准治疗未对WHO 1-4级胶质瘤患者认知功能产生有害影响,辅助治疗患者认知表现与无辅助治疗者相当。
研究设计与样本
- 前瞻性随访研究,纳入2004至2012年在德国胶质瘤网络治疗的86例WHO 1-4级胶质瘤患者,使用计算机化测验组合NeuroCog FX进行系列神经心理学评估。
主要发现
- 术后基线至随访中位16.8个月(范围5.9-31.1个月),所有治疗组各认知域均数值改善且常达统计学显著,治疗组间认知变化程度无差异。
- 仅图形记忆方面,照射患者改善少于未照射患者(p=0.029,η2=0.06)。
- 切除患者所有认知域均改善,活检患者未改善;少突胶质细胞瘤患者注意和执行功能改善潜力大于星形细胞瘤患者。
局限性
- 患者组异质性和可能的选择性队列可能混杂结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cognitive functioning represents an essential determinant of quality of life. Since significant advances in neuro-oncological treatment have led to prolonged survival it is important to reliably identify possible treatment-related neurocognitive dysfunction in brain tumor patients. Therefore, the present study specifically evaluates the effects of standard treatment modalities on neurocognitive functions in glioma patients within two years after surgery. METHODS: Eighty-six patients with World Health Organization (WHO) grade 1-4 gliomas were treated between 2004 and 2012 and prospectively followed within the German Glioma Network. They received serial neuropsychological assessment of attention, memory and executive functions using the computer-based test battery NeuroCog FX. As the primary outcome the extent of change in cognitive performance over time was compared between patients who received radiotherapy, chemotherapy or combined radio-chemotherapy and patients without any adjuvant therapy. Additionally, the effect of irradiation and chemotherapy was assessed in subgroup analyses. Furthermore, the potential impact of the extent of tumor resection and histopathological characteristics on cognitive functioning were referred to as secondary outcomes. RESULTS: After a median of 16.8 (range 5.9-31.1) months between post-surgery baseline neuropsychological assessment and follow-up assessment, all treatment groups showed numerical and often even statistically significant improvement in all cognitive domains. The extent of change in cognitive functioning showed no difference between treatment groups. Concerning figural memory only, irradiated patients showed less improvement than non-irradiated patients (p = 0.029, η2 = 0.06). Resected patients, yet not patients with biopsy, showed improvement in all cognitive domains. Compared to patients with astrocytomas, patients with oligodendrogliomas revealed a greater potential to improve in attentional and executive functions. However, the heterogeneity of the patient group and the potentially selected cohort may confound results. CONCLUSION: Within a two-year post-surgery interval, radiotherapy, chemotherapy or their combination as standard treatment did not have a detrimental effect on cognitive functions in WHO grade 1-4 glioma patients. Cognitive performance in patients with adjuvant treatment was comparable to that of patients without.
引用
- Schlömer S, Felsberg J, Pertz M, et al. Mid-term treatment-related cognitive sequelae in glioma patients. J Neurooncol. 2022. PMID: 35796933. doi:10.1007/s11060-022-04044-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。